Life Science & Biotech

Greenwood biotech firm's assets to hit auction block

September 3, 2013
 IBJ Staff
The remnants of ill-fated Elona Biotechnologies Inc. will be auctioned on Sept. 27, presenting a rare turnkey opportunity for entrepreneurs interested in jumping into the life sciences industry.
More

Board suggested busy Evans let go of AIT

August 5, 2013
J.K. Wall
Michael Evans was juggling two companies and two newborn twins when his board of directors suggested it was time for a new CEO of AIT Laboratories. He was replaced by venture capitalist Matt Neff on Monday.
More

Life sciences venture capital dips againRestricted Content

August 3, 2013
J.K. Wall
Venture capital surged in the first half of 2012, to $51.6 million in Indiana. But the pace of activity here fell off sharply in the second half of last year, and remained sluggish into 2013.
More

Zimmer earnings fall on legal reserve costs

July 25, 2013
Associated Press
Zimmer Holdings saw second-quarter earnings slump 29 percent as the orthopedic device maker set aside an additional $47 million to cover the cost of lawsuits related to its Durom hip cups.
More

Dow AgroSciences posts record second-quarter sales

July 25, 2013
 IBJ Staff and Associated Press
The Indianapolis-based maker of agricultural products, a unit of Michigan-based Dow Chemical Co., said revenue increased 10 percent from the year-ago period.
More

Universities' patents often lack commercial applicationsRestricted Content

July 6, 2013
Dan Human
The state's universities crank out patents that find their way to pharmaceutical, prosthetics and surgery technology companies. But they also generate reams of patents in areas with few industrial applications.
More

Cook Group looking forward to next 50 years

July 2, 2013
Associated Press
For leaders of a company looking back on 50 years of existence, Cook Group President Kem Hawkins and Chairman Steve Ferguson spend a lot of time talking about the future.
More

Lilly Endowment to give $10M to start biosciences institute

June 27, 2013
J.K. Wall
The institute aims to attract 100 new scientists to Indiana to conduct research and development work aimed at launching new therapies for metabolic diseases.
More

Most of Indiana's largest public companies enjoyed strong 2012Restricted Content

June 15, 2013
Angie's List turned a profit for the first time in nearly two decades.
More

Lilly halts trial of experimental Alzheimers drug

June 14, 2013
The trial ended after participants showed abnormal liver biochemistry, the Indianapolis-based drugmaker said Thursday in a statement.
More

Bio-Response expanding in Hendricks County

June 10, 2013
 IBJ Staff
Wastewater equipment maker is moving to a Danville business park to build a $1.1 million facility.
More

New institute aims to attract 100 research scientists to Indiana

May 30, 2013
J.K. Wall
The $360 million initiative will be formally launched on Thursday by Gov. Mike Pence, executives of five major life sciences companies and officials of the state’s research universities.
More

Mobile health apps could cut into state companies' market share

May 18, 2013
J.K. Wall
The future of Indiana’s sprawling health care and life sciences industry might be threatened by an unlikely source: smartphone apps.
More

PINCUS: State needs better life sciences startup ecosystem

May 18, 2013
Jack Pincus / Special to IBJ
Indiana’s life sciences sector is mostly composed of legacy companies.
More

Report: Roche mulls sale of blood-glucose monitor business

May 17, 2013
J.K. Wall
Roche Diagnostics Corp. is considering a sale of its blood-glucose meter business, a move that would cast uncertainty over the nearly 1,000 people working for its diabetes business in Indianapolis.
More

PANEL: Life sciences will see radically different futureRestricted Content

May 17, 2013
IBJ convened a panel of experts at its Life Sciences Power Breakfast on May 10 to talk about the industry issues of venture capital, digital health innovations and research university entrepreneurship.

Panel members included Kristin Eilenberg, CEO, Lodestone Logic, Infuse Accelerator; Philip S. Low, Purdue University professor of chemistry, founder and chief science officer at Endocyte Inc. and On Target Laboratories LLC; R. Matthew Neff, president, CHV Capital Inc.; Brian Stemme, project director; BioCrossroads; Brian S. Williams, director, Global Healthcare Strategy, PricewaterhouseCoopers International Ltd.; and Raul Zaveleta, CEO, Indigo BioSystems Inc.

The following is an unedited transcript of the discussion.

More

New seed fund aims to make Indiana a hotbed for digital health startupsRestricted Content

May 4, 2013
J.K. Wall
Infuse Accelerator hopes to make early-stage investments in 12 to 15 companies a year.
More

Lilly suing J&J for patent rights in Alzheimer's drug race

April 25, 2013
Bloomberg News
Eli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer’s disease.
More

Dow AgroSciences grows sales, earnings to new heights

April 25, 2013
Mason King, Bloomberg News
Record sales for seeds and new crop protection products helped boost revenue 14 percent at Indianapolis-based Dow AgroSciences LLC in its new fiscal year.
More

Lilly seeks $30.6M in tax breaks on downtown projects

April 15, 2013
Mason King
Indianapolis development officials on Wednesday will weigh the 10-year requests from the pharmaceuticals giant related to a new manufacturing plant and improvements to existing operations downtown.
More

IU medical school's push to launch startups bears fruitRestricted Content

April 13, 2013
J.K. Wall
The Indiana University School of Medicine has launched 12 companies in the past 18 months—a burst of startup activity the school has never seen before.
More

Expected revenue slump spurs Lilly to cut sales force

April 11, 2013
J.K. Wall
The Indianapolis pharmaceuticals giant said Thursday that it would lay off hundreds of U.S. sales reps, as it prepares for the loss of patent protection on two of its best-selling drugs.
More

City to buy key parcel for 16th Street tech corridorRestricted Content

April 6, 2013
Scott Olson
The city of Indianapolis is poised to pay Citizens Energy Group $6.5 million to buy a key parcel of real estate it’s targeting as the centerpiece of its ambitious 16 Tech project.
More

Lilly pulls back from proposals lowering takeover barriersRestricted Content

April 6, 2013
Greg Andrews
Fortunately, a Lilly takeover looks less likely today than it has in a long time—for both obvious and more subtle reasons.
More

Lilly to spend $180M doubling size of Indy plant

April 2, 2013
The new investment will bring the plant's total price tag to $320 million as the pharmaceutical giant seeks to increase production of insulin and related products.
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. With Pence running the ship good luck with a new government building on the site. He does everything on the cheap except unnecessary roads line a new beltway( like we need that). Things like state of the art office buildings and light rail will never be seen as an asset to these types. They don't get that these are the things that help a city prosper.

  2. Does the $100,000,000,000 include salaries for members of Congress?

  3. "But that doesn't change how the piece plays to most of the people who will see it." If it stands out so little during the day as you seem to suggest maybe most of the people who actually see it will be those present when it is dark enough to experience its full effects.

  4. That's the mentality of most retail marketers. In this case Leo was asked to build the brand. HHG then had a bad sales quarter and rather than stay the course, now want to go back to the schlock that Zimmerman provides (at a considerable cut in price.) And while HHG salesmen are, by far, the pushiest salesmen I have ever experienced, I believe they are NOT paid on commission. But that doesn't mean they aren't trained to be aggressive.

  5. The reason HHG's sales team hits you from the moment you walk through the door is the same reason car salesmen do the same thing: Commission. HHG's folks are paid by commission they and need to hit sales targets or get cut, while BB does not. The sales figures are aggressive, so turnover rate is high. Electronics are the largest commission earners along with non-needed warranties, service plans etc, known in the industry as 'cheese'. The wholesale base price is listed on the cryptic price tag in the string of numbers near the bar code. Know how to decipher it and you get things at cost, with little to no commission to the sales persons. Whether or not this is fair, is more of a moral question than a financial one.

ADVERTISEMENT